|Gastrointestinal Diseases Drug Development Pipeline Review, 2018: Gastroenteritis, Enterocolitis, Gastritis and Peritonitis - ResearchAndMarkets.com|
|Friday, 11 January 2019 00:06|
Jan. 11, 2019 10:47 UTC
Gastrointestinal Diseases Drug Development Pipeline Review, 2018: Gastroenteritis, Enterocolitis, Gastritis and Peritonitis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)-- The "Gastrointestinal Diseases Drug Development Pipeline Review 2018" report has been added to ResearchAndMarkets.com's offering.
Gastrointestinal Diseases Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for gastrointestinal diseases.
It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products.
Molecular targets in development for gastrointestinal diseases include toll-like receptors, interleukin receptors and bacterial proteins. Companies operating in this pipeline space include Kyowa Hakko Kirin, RedHill Biopharma and GlaxoSmithKline.
1 Table of Contents
3 Therapeutics Development
4 Therapeutics Assessment
5 Companies Involved in Therapeutics Development
6 Dormant Projects
7 Discontinued Products
8 Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/vjw5x7/gastrointestinal?w=4
Source: Research and Markets